Selegiline, also known as l-deprenyl, is an antidepressant drug used to treat major depressive disorder, Parkinson’s disease, and Alzheimer’s disease. It is a monoamine oxidase inhibitor (MAOI) that has been used since the late 1980s to treat depression. While selegiline has been found to be effective in treating depression, there are some hidden side effects that doctors should be aware of. This article will explore the potential hidden side effects of selegiline and discuss ways to uncover the unknown.
Selegiline is an MAOI that works by blocking the enzyme monoamine oxidase from breaking down certain neurotransmitters, such as dopamine and norepinephrine. This allows these neurotransmitters to remain active in the brain longer, providing a mood boost. Selegiline is generally prescribed to treat major depressive disorder, Parkinson’s disease, and Alzheimer’s disease.
While selegiline has been found to be effective in treating depression, there are some hidden side effects that doctors should be aware of. The most common side effects of selegiline are nausea, vomiting, headache, insomnia, dry mouth, dizziness, and constipation. Other potential hidden side effects include anxiety, irritability, confusion, agitation, and hallucinations. Selegiline can also cause an increase in blood pressure and heart rate, which can be dangerous for those with pre-existing heart conditions.
Certain factors can increase the risk of experiencing hidden side effects from selegiline. These include age, gender, weight, and other medications being taken. Elderly patients are more likely to experience hidden side effects from selegiline, as they may have a lower tolerance for the drug. Women are also more likely to experience hidden side effects than men. Those who are overweight or obese may be more likely to experience hidden side effects due to the increased metabolism of the drug. Finally, those who are taking other medications may be more likely to experience hidden side effects due to potential drug interactions.
Due to the potential for hidden side effects, it is important for doctors to take steps to uncover the unknown. One way to do this is to discuss the potential side effects of selegiline with patients before they start taking the medication. It is also important to monitor patients closely while they are taking the medication, as this can help to identify any potential hidden side effects. Finally, doctors should be aware of any potential drug interactions and discuss them with patients before prescribing selegiline.
Selegiline is an effective treatment for major depressive disorder, Parkinson’s disease, and Alzheimer’s disease. However, there are some potential hidden side effects that doctors should be aware of. By discussing the potential side effects of selegiline with patients before they start taking the medication, monitoring patients closely while they are taking the medication, and being aware of any potential drug interactions, doctors can help to uncover the unknown and ensure that patients receive the best possible care.
1.
Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients
2.
In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.
3.
Kidney cancer: Understanding what a renal cell carcinoma diagnosis means
4.
AI tool automates liver tumor detection and monitoring
5.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
1.
Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection
2.
Advances in Cancer Detection: From Genetic Risk to Molecular Biomarkers
3.
Unlocking the Power of Cryoprecipitate: A Comprehensive Guide
4.
How Cancer Cells Evade Immune Destruction and the Fight Back
5.
Unlocking The Causes And Risk Factors Of Breast Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
2.
Current Scenario of Cancer- Q&A Session to Close the Gap
3.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation